Welcome to our dedicated page for CLOVER HEALTH INVESTMENTS /DE SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOVER HEALTH INVESTMENTS /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOVER HEALTH INVESTMENTS /DE's regulatory disclosures and financial reporting.
Soares Karen reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments, Corp. reported that Chief Legal Officer Karen Soares received a grant of 108,695 shares of Class A Common Stock in the form of time-based restricted stock units. The award vests 25% on the first anniversary of August 12, 2026, with the remainder vesting in twelve equal quarterly installments beginning three months after that anniversary, subject to her continued service, and brings her directly held shares to 1,614,217.
THORNTON JOSEPH CLAY reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments reported that Interim CFO Joseph Clay Thornton received a grant of 54,347 shares of Class A Common Stock in the form of time-based restricted stock units (RSUs) on August 12, 2026. Twenty-five percent of these RSUs vest on the first anniversary of that date, with the remainder vesting in twelve equal quarterly installments until full vesting on August 12, 2030, subject to his continued service. Following this award, Thornton beneficially owns 1,267,301 shares of Class A Common Stock.
Clover Health Investments, Corp. director and Chief Executive Officer Andrew Toy reported a sale of 87,798 shares of Class A Common Stock on August 10, 2026 at a weighted average price of $4.65 per share. The shares were sold solely to cover tax withholding obligations tied to the final vesting on August 8, 2026 of 6.25% of restricted stock units granted on August 8, 2022, under a mandated "sell to cover" election, and are described as non‑discretionary transactions. Following this sale, Toy directly holds 9,459,316 shares of Class A Common Stock.
CLOV Class A common stock is scheduled to be sold through Morgan Stanley Smith Barney LLC, with up to 85,704 shares valued at $391,667.28 relative to 435,441,337 shares outstanding, targeting around 08/10/2026 on Nasdaq. These shares stem from Restricted Stock Units acquired as compensation on 08/08/2026. The disclosure also lists prior Rule 10b5-1 plan sales by Andrew Toy of 313,476 shares for $1,667,692.32 on 07/01/2026 and 62,711 shares for $292,860.37 on 07/15/2026.
Clover Health Investment Corp. investor Brady Priest filed a Form 144 covering proposed sales of common stock. The notice lists two planned sales related to stock option exercises dated August 7, 2026, for 79,349 and 362,252 shares. It also reports a prior sale of 98,039 common shares on May 13, 2026 for $345,107.08, routed through Morgan Stanley Smith Barney LLC Executive Financial Services.
Clover Health Investments reported results for the quarter ended June 30, 2026. Total revenues were $743.2 million, up 55.6% year-over-year, driven by Medicare Advantage growth. GAAP net income was $28.0 million, compared with a net loss of $10.6 million a year earlier, and diluted earnings per share were $0.05.
Average Medicare Advantage membership reached 156,840, up 48.7%, with 157,309 insurance members at June 30, 2026. Consolidated Gross profit (non-GAAP) was $153.0 million, up 53.6%, and Adjusted EBITDA was $40.9 million, up 139.2% year-over-year. Insurance Benefits Expense Ratio was 87.6%, an 80-basis-point improvement.
The company raised full-year 2026 guidance to total revenues of $2.92–$3.00 billion, Consolidated Gross profit of $525–$555 million, Adjusted EBITDA of $70–$85 million, GAAP net income of $20–$35 million, and average Medicare Advantage membership of 156,000–158,000. Cash, cash equivalents, and investments totaled $443.0 million at June 30, 2026.
Clover Health Investments, Corp. Chief Legal Officer Karen Soares sold 51,700 shares of Class A Common Stock on July 20, 2026, reported as a sale in the open market or a private transaction at a $4.51 weighted average price, with individual prices from $4.46 to $4.59, pursuant to a 10b5-1 plan adopted on March 13, 2026. Following this sale, she directly holds 1,505,522 shares.
Clover Health Investments (CLOV) insider Karen Soares filed to sell up to 51,700 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an aggregate market value of $238,854.00. The securities relate to Restricted Stock Units granted on 03/15/2026, with additional sales already made in the past three months.
Clover Health Investments, Corp. executive Jamie L. Reynoso, CEO, Medicare Advantage, sold 4,839 shares of Class A Common Stock on July 17, 2026, at a $4.53 weighted average price, in multiple trades between $4.35 and $4.63 per share, under a Rule 10b5-1 trading plan adopted March 12, 2026. Following this sale, Reynoso directly holds 2,814,640 shares of Class A Common Stock.